prof.dr. W.H. van Harten (Wim)

Wim H. van Harten graduated as M.D. and specialized in tropical medicine. On returning from Africa he focused on public health and health administration. He obtained a degree in community medicine/public and worked Chief Medical Advisor of a major health insurance company (1986-1992). Thereafter worked as CEO at t the rehabilitation hospital “Het Roessingh” in Enschede and as member of the Executive Board of the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL). I Since 2015 he is CEO at Rijnstate Hospital Arnhem. From 2005 onwards he was appointed as Research Group leader at the Division of Psychosocial Research and Epidemiology at the NKI.

Since 2001 he is part-time professor on “Quality Management and Health Care Technology” at the department of Health Technology and Services Research of the School of Management and Governance. So far, he supervised over 20 Ph.D graduations and presently his group consists of 1 postdoc and 5 PhD students in the NKI and 5 in other universities. He published over 200 peer reviewed papers on health services and quality management, especially Health Technology Assessment, E-health and Process improvement.

He served as President of the OECI from 2011-2014, presently as Chair OECI Working Group on Health Economics and member of the OECI Cancer Center Accreditation and Designation Board. From 2008 – 2014 he served as Board member of the Netherlands Hospital Association with the portfolio of innovation, drug costs and quality issues.

From 2015 he is CEO of Rijnstate (general) Hospital in Arnhem, a large teaching hospital with an annual expenditure of € 600 million and around 5500 employees, of whom around 300 medical specialists and 110 MDs in specialist training. He is Chair of mProve, a collaborative of 7 large teaching hospitals in the Netherlands with a total annual expenditure of ± € 4 billion.

Medicine & Life Sciences

# Biomedical Technology Assessment
# Breast Neoplasms
# Cancer Survivors
# Cost-Benefit Analysis
# Costs And Cost Analysis
# Exercise
# Neoplasms

Social Sciences

# Cancer

Faculty of Behavioural, Management and Social Sciences (BMS), Health Technology & Services Research (HTSR)

The Netherlands Cancer Institute
Research group Leader
OECI
Accreditation & Designation Board and Working Group Health Economics European Organisation of Cancer Institutes (OECI)
VAN - Strategy & Improvement
Consultancy and Interim Assignments

Western, B., Ivarsson, A., Vistad, I., Demmelmaier, I., Aaronson, N. K., Radcliffe, G., van Beurden, M., Bohus, M., Courneya, K. S., Daley, A. J., Galvão, D. A., Garrod, R., Goedendorp, M. M., Griffith, K. A. , van Harten, W. H., Hayes, S. C., Herrero-Roman, F., Hiensch, A. E., Irwin, M. L., ... Buffart, L. M. (2024). Dropout from exercise trials among cancer survivors—An individual patient data meta-analysis from the POLARIS study. Scandinavian Journal of Medicine and Science in Sports, 34(2), Article e14575. https://doi.org/10.1111/sms.14575

Koning, N. J., Lokin, J. L. C., Roovers, L., Kallewaard, J. W. , van Harten, W. H., Kalkman, C. J., & Preckel, B. (2024). Introduction of a Post-Anaesthesia Care Unit in a Teaching Hospital Is Associated with a Reduced Length of Hospital Stay in Noncardiac Surgery: A Single-Centre Interrupted Time Series Analysis. Journal of Clinical Medicine, 13(2), Article 534. https://doi.org/10.3390/jcm13020534

Peters, G. M. (2024). Exploring the potential of virtual care. [PhD Thesis - Research external, graduation UT, University of Twente]. University of Twente. https://doi.org/10.3990/1.9789036560443

Vancoppenolle, J. M. , Franzen, N., Koole, S. N. , Retèl, V. P. , & van Harten, W. H. (2024). Differences in time to patient access to innovative cancer medicines in six European countries. International journal of cancer, 154(5), 886-894. https://doi.org/10.1002/ijc.34753

Ven, M. V. D. , Koffijberg, H. , Retèl, V. P. J. , Harten, W. H. V. , & IJzerman, M. J. (2023). Dynamic Simulation Modeling to Analyze the Impact of Whole Genome Sequencing National Implementation Scenarios in Lung cancer on Time-to-Treatment, Costs and Patient Demand. MedRxiv. https://doi.org/10.1101/2023.11.10.23298371

Hiensch, A. E., Beckhaus, J., Witlox, L., Monninkhof, E. M., Schagen, S. B., van Vulpen, J. K., Sweegers, M. G., Newton, R. U., Aaronson, N. K., Galvão, D. A., Steindorf, K., Stuiver, M. M., Mesters, I., Knoop, H., Goedendorp, M. M., Bohus, M., Thorsen, L., Schulz, K. H., Schmidt, M. E., ... May, A. M. (2023). Moderators of exercise effects on self-reported cognitive functioning in cancer survivors: an individual participant data meta-analysis. Journal of cancer survivorship. Advance online publication. https://doi.org/10.1007/s11764-023-01392-3

Vancoppenolle, J. M., Koole, S. N., O'Mahony, J. F. , Franzen, N., Burgers, J. A. , Retèl, V. P. , & van Harten, W. H. (2023). Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe. Drug discovery today, 28(8), Article 103620. https://doi.org/10.1016/j.drudis.2023.103620

Wind, A., Oberst, S., Westerhuis, W., Blaauwgeers, H., Sæter, G., de Paoli, P., Nagy, P., Burrion, J. B., Jolly, E., Lovey, J. , & van Harten, W. (2023). Evaluating comprehensive cancer networks; a review of standards and evaluation methods for care networks to inform a comparison with the OECI comprehensive cancer network standards. Acta oncologica, 62(1), 15-24. https://doi.org/10.1080/0284186X.2023.2170275

Ploem, M. C., Giesbertz, N. A. A., Bredenoord, A. L. , Retèl, V. P. , & van Harten, W. H. (2023). Duty to recontact in genomic cancer care: A tool helping to assess the professional's responsibility. European journal of cancer, 186, 22-26. https://doi.org/10.1016/j.ejca.2023.03.004

Verbeek, J. G. E., de Jong, V. M. T., Wijnja, H. M., Jager, A., Linn, S. C. , Retèl, V. P. , & van Harten, W. H. (2023). High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation. BMC cancer, 23(1), Article 26. https://doi.org/10.1186/s12885-022-10412-x

See all research output of this employee

Courses in the current academic year are added at the moment they are finalised in the Osiris system. Therefore it is possible that the list is not yet complete for the whole academic year.

+31534894429

+31534897475 (secretary)

+31534897475 (if no answer)

w.h.vanharten@utwente.nl

Visiting Address

University of Twente
Faculty of Behavioural, Management and Social Sciences
Technohal (building no. 18), room 3105
Hallenweg 5
7522NH Enschede
The Netherlands

Navigate to location

Mailing Address

University of Twente
Faculty of Behavioural, Management and Social Sciences
Technohal 3105
P.O. Box 217
7500 AE Enschede
The Netherlands

Faculty of Behavioural, Management and Social Sciences (BMS), Health Technology & Services Research (HTSR)

University of Twente Drienerlolaan 5
7522 NB Enschede

+31 (0)53 489 9111
info@utwente.nl
Route

Welcome...

Professor Quality Management and Health Care Technology

About Me

Expertise

Organisations

Ancillary Activities

Publications

UT Research Information System

Courses Academic Year 2023/2024

Courses Academic Year 2022/2023

Contact Details

Visiting Address

Mailing Address

Organisations